On October 9, 2018 AstraZeneca and MedImmune, its global biologics research and development arm, reported that it will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) (ESMO 2018) Congress in Munich, Germany, 19-23 October (Press release, AstraZeneca, OCT 9, 2018, View Source [SID1234529815]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data span several tumour types and include full results from the Phase III SOLO-1 ovarian cancer trial to be presented in the Presidential Symposium, along with new research on resistance mechanisms in metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In addition, MedImmune Senior Vice President, Head of Oncology Innovative Medicines and Professor of Medicine and Medical Oncology at South-Paris University, Jean-Charles Soria, will be recognised for his outstanding contribution to medical oncology by receiving the 2018 ESMO (Free ESMO Whitepaper) Award.
Dave Fredrickson, Executive Vice President, Head of Oncology Business Unit, said: "Our diversified Oncology portfolio prioritises medicines with the potential to redefine the clinical practice of cancer treatment. We are working to deliver potentially curative approaches earlier in the treatment paradigm across a range of cancers. We are also exploring how to stay a step ahead of disease progression by understanding how tumours become resistant to treatment over time."
Detailed Lynparza data from the Phase III SOLO-1 trial in women with newly-diagnosed, advanced BRCA-mutated ovarian cancer
SOLO-1 is the only trial of a poly (ADP-ribose) polymerase (PARP) inhibitor, Lynparza, to demonstrate a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for women with newly-diagnosed, advanced BRCA-mutated ovarian cancer. Data from the trial by AstraZeneca and MSD, known as Merck in the US and Canada, will be featured in an ESMO (Free ESMO Whitepaper) Presidential Symposium (Presentation #LBA7_PRAbstract). In the 1st-line setting, only 20 percent of women have prolonged, relapse-free periods and are considered cured following surgery and chemotherapy, and 70 percent relapse within three years. These data will provide detailed PFS results for Lynparza, supporting the treatment goal of long-term remission in women with newly-diagnosed disease, where currently-available treatment options aimed at extending time to progression only offer modest improvements.
New understanding of acquired resistance mechanisms in lung cancer from the Phase III FLAURA trial
Preliminary data on acquired resistance mechanisms seen with 1st-line Tagrisso (osimertinib) use in the Phase III FLAURA trial (Presentation Number #LBA_5005) will be presented as a late-breaker, providing new insights into potential treatment strategies for patients with metastatic EGFR-mutated NSCLC.
Lung cancer Immuno-Oncology (IO): New insights from the Phase III PACIFIC trial
An oral presentation of subgroup analyses will explore the efficacy and safety of the PACIFIC regimen in unresectable, Stage III NSCLC evaluating differences in treatment and timing for chemoradiation therapy before Imfinzi (Abstract #1363O).
Early pipeline explores combinations in difficult-to-treat tumour types
Key presentations from AstraZeneca’s early stage pipeline include insight into novel DNA Damage Response (DDR)-IO combinations. A Phase I clinical and translational evaluation of the ATR inhibitor, AZD6738, in combination with Imfinzi in patients with lung or head and neck cancer will be featured as a poster discussion (Abstract #413PD).
Data from the early-stage IO pipeline, including updated results from the Phase Ib/II multi-indication SCORES trial of Imfinzi plus danvatirsen (AZD9150, STAT3) or AZD5069 (CXCR2), demonstrating the impact of targeting novel pathways, will also be presented (Abstract #1044O).
Additionally, new approaches to patient selection using different methods of detection of homologous recombination repair gene mutations will be highlighted in a Phase II trial of Lynparza plus abiraterone (Study 08) in metastatic castration-resistant prostate cancer (Abstract #97P).
Key AstraZeneca/MedImmune presentations at ESMO (Free ESMO Whitepaper) 2018:
Lead author
Abstract title
Presentation details
Ovarian cancer
Moore, K
Phase III SOLO1 trial: Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced stage ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm)
Oral Presentation
Presidential Symposium 2
Sunday 21st October, 16:30-18:10
Presentation Time: 17:45-18:00
Location: Hall A2, Room 18
Abstract #LBA7_PR
Penson, RT
MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in patients with advanced solid tumors – new ovarian cancer cohorts
Poster
Gynaecological cancers
Monday 22nd October, 12:45-13:45
Location: Hall A3
Abstract #448TiP
Colombo, N
BAROCCO: A randomized phase II study of weekly paclitaxel vs. cediranib-olaparib with continuous schedule vs. cediranib-olaparib with intermittent schedule in advanced platinum-resistant ovarian cancer
Poster
Gynaecological cancers
Saturday 20th October, 12:30-13:30
Location: Hall A3
Abstract #1002TiP
Lung Cancer
Ramalingam, S
Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study
Oral Presentation
NSCLC, metastatic
Friday 19th October, 16:00-17:30
Presentation Time: 16:00-16:12
Location: Hall A2, Room 18
Abstract #LBA50
Faivre-Finn, C
Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
Oral Presentation
Non-Metastatic NSCLC and Other Thoracic Malignancies
Sunday 21st October, 09:15-10:45
Presentation Time: 10:15-10:30
Location: Hall A1, Room 17
Abstract #1363O
Kowalski, D
ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥3L advanced NSCLC treatment
Oral Presentation
NSCLC, metastatic
Monday 22nd October, 09:15-11:00
Presentation Time: 10:15-10:30
Location: Hall A1, Room 17
Abstract #1378O
Bondarenko, I
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from Arm A of the Phase II BALTIC study
Poster Discussion
Lung early
Sunday 21st October, 14:45-16:00
Discussion Time: 15:25-15:35
Location: ICM, Room 1
Abstract #1665PD
Early pipeline
Cohen, EW
Phase 1b/2 Study (SCORES) of Durvalumab (D) Plus AZD9150 or AZD5069 in Advanced Solid Malignancies and Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN): Updated Results
Oral Presentation
Head & Neck cancer
Monday 22nd October, 14:45-16:15
Presentation Time: 14:45-15:00
Location: ICM, Room 14b
Abstract #1044O
Krebs, MG
Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
Poster Discussion
Developmental therapeutics
Saturday 20th October, 15:00-16:15
Discussion Time: 15:00-15:20
Location: Hall B3, Room 22
Abstract #413PD
Carr, Thomas H
Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Poster
Biomarkers
Saturday 20th October, 12:30-13:30
Location: Hall A3
Abstract #97P